ORUKA THERAPEUTICS INC. - COMMON STOCK

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

19 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

18 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference

19 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

13 Nov 2024 15:25:13 By Nasdaq GlobeNewswire

Oruka Therapeutics to Present at Multiple November Investor Conferences

04 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

25 Sep 2024 06:08:51 By Nasdaq GlobeNewswire

Oruka Therapeutics Announces $200 Million Private Placement

12 Sep 2024 06:05:00 By Nasdaq GlobeNewswire

Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19

12 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million

03 Sep 2024 06:00:00 By Nasdaq GlobeNewswire